Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04445792 · ClinicalTrials.gov registry record · NA
A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 4,284
- Enrollment target
NCT04445792: Completed NA study, sponsored by Duke University.
NCT04445792 is a NA study that has completed, run by Duke University. The registered enrollment target is 4,284 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (205% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04445792, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,284 participants
- Enrollment target
Study Summary
This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depression Trial. Participants can enroll in only one of the three trials. Each trial is listed individually on clinicaltrials.gov and includes "PRO00104948" within the Unique Protocol ID: PRO00104948\_A - Acute Pain Trial - NCT05966129 PRO00104948\_B - Chronic Pain Trial - NCT05966142 PRO00104948\_C - Depression Trial - NCT05966155 Acute Pain Trial: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided post-surgical opioid therapy (Intervention arm) or standard care and pharmacogenetic testing after 6 months (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain management therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal. Chronic Pain Trial: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided opioid therapy (Intervention arm) or standard care with 6-month delayed pharmacogenetic testing (Control arm). The investigators will test the hypothesis that pharmacogenetic testing and genotype guided pain therapy improves pain control after surgery in participants who's body processes some pain medicines slower than normal. Depression: A prospective, multicenter, two arm randomized pragmatic trial. Participants meeting eligibility criteria will be randomly assigned to either immediate pharmacogenetic testing and genotype-guided anti-depressant therapy (Intervention arm) or
Primary Outcome
Potential participants identified for the Acute Pain, Chronic Pain, and Depression Trials through EHR.
Interventions
- OTHER Pharmacogenetic testing
- OTHER Clinical decisions support
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,284 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2024-05-10 |
| Phase | NA |
What the finished NCT04445792 record still lists
NCT04445792 is an interventional study that assigns participants to a tested intervention. Its 4,284 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (205% higher).
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic testing is the first listed.
NCT04445792 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04445792 about?
NCT04445792 is a clinical study titled "A Depression and Opioid Pragmatic Trial in Pharmacogenetics (DCRI Coordinating Center)". This is a Master Protocol Screening record. This study is comprised of three separate pharmacogenetic trials grouped into a single protocol due to similarities in the intervention, the hypotheses, and the trial design. The three trials are the Acute Pain Trial, the Chronic Pain Trial, and the Depres...
What is the current status of trial NCT04445792?
This trial is currently completed. It is a NA study. The enrollment target is 4,284 participants. The study started on 2021-02-24. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT04445792?
The interventions under investigation include: Pharmacogenetic testing (OTHER), Clinical decisions support (OTHER).
Who is sponsoring clinical trial NCT04445792?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04445792's enrollment target sits among peer trials
4,284 30th of 2000 higher than 1,971 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI